{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039171","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.146824+00:00","generated_at":"2026-06-09T00:59:01.059017+00:00","sec_items":["1.01","3.03","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biofrontera raises $4.5M in registered direct offering, amends existing warrants to $3.55","bullets":["Gross proceeds of ~$4.5M from sale of 1,205,000 shares/pre-funded warrants and 1,807,500 common warrants.","Common warrants exercisable at $3.55/share, expire 5 years from issuance; pre-funded warrants at $0.0001.","Existing warrants for 385,236 shares amended to $3.55 exercise price and extended to November 2, 2028.","Roth Capital Partners acted as placement agent; cash fee of 7% of gross proceeds plus expenses.","Net proceeds to be used for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039171","json":"https://secwatch.observer/filing/0001493152-23-039171.json","markdown":"https://secwatch.observer/filing/0001493152-23-039171.md","text":"https://secwatch.observer/filing/0001493152-23-039171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/0001493152-23-039171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:59:01.059017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82f2870b4ce70b8f753d4b27e4d1c0cde9c147ca","claim":"Biofrontera Inc. amended Existing Warrants Amendment with an institutional investor valued at Amendment to revise exercise price to $3.55 and extend expiration date to November 2, 2028 (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, in connection with the Purchase Agreement, the Company entered into an amendment to the Existing Warrants (the “ Existing Warrants Amendment ”) pursuant to which the Company agreed, effective November 2, 2023, to (i) revise the exercise price of the Existing Warrants to $3.55 and (ii) extend the date until which the Existing Warrants can be exercised until November 2, 2028.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/0001493152-23-039171-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"Amendment to revise exercise price to $3.55 and extend expiration date to November 2, 2028"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"},{"claim_id":"dfca6f6a3ce06c4fe1a3fe2db3210838679f3169","claim":"Biofrontera Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at Gross proceeds of approximately $4.5 million from sale of 1,205,000 shares of common stock and warra (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “ Placement Agency Agreement ”) with Roth Capital Partners, LLC (the “ Placement Agent ”) and a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor for the purchase and sale, in a registered public offering by the Company (the “ Public Offering ”) of an aggregate of 1,205,000 shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), or pre-funded warrants to purchase Common Stock in lieu thereof, each of which is coupled with a warrant to purchase one and one-half shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/0001493152-23-039171-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Value","value":"Gross proceeds of approximately $4.5 million from sale of 1,205,000 shares of common stock and warra"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}